Clinical Trials Logo

Filter by:
NCT ID: NCT06326736 Recruiting - Pancreatic Cancer Clinical Trials

Study of Neoantigen mRNA Vaccines in Patients With Resectable Pancreatic Cancer

Start date: April 2024
Phase: Early Phase 1
Study type: Interventional

The purpose of this study is to evaluate the safety and efficacy of treating pancreatic cancer with surgery to remove cancerour tissue, followed by camrelizumab and a personalized cancer mRNA vaccines.

NCT ID: NCT06325995 Recruiting - Clinical trials for Localized Prostate Cancer

Hypofractionated Post-prostatectomy Radiotherapy (HYPORT)for Localized Prostate Cancer

Start date: October 1, 2023
Phase: N/A
Study type: Interventional

The aim of this trial is to compare the safety outcomes of Hypofractionated postprostatectomy radiotherapy (HYPORT) and Conventionally fractionated postprostatectomy radiotherapy(COPORT) in treating patients with localized prostate cancer. Accumulating evidence has proven the safety and feasibility of HYPORT for localized prostate cancer.But for localized prostate cancer,the optimal dose per fraction of HYPORT is still on its way. It is not yet known whether giving HYPORT(57.5-65 Gy in 23-26 daily fractions of 2.5 Gy ) with or COPORT may work better in treating patients with prostate cancer.

NCT ID: NCT06325982 Recruiting - Rectal Diseases Clinical Trials

Clinical Observation of Drug Retention Enema in Preventing Acute Radiation-induced Rectal Injury

Start date: June 11, 2024
Phase: N/A
Study type: Interventional

The main objective of this study was to evaluate the efficacy and safety of drug retention enema for the prevention of acute radiation rectal injury in the real world.

NCT ID: NCT06325969 Recruiting - Metformin Clinical Trials

PCOS Patients Immune Status Evaluation

Start date: March 16, 2024
Phase:
Study type: Observational

In this study, the investigators will include PCOS patients and healthy women who meet the trial criteria from the clinical research centers of 3 hospitals, introduce the content of this study to participants, and invite participants to participate. Flow cytometry was used to detect the immune function of peripheral blood samples of PCOS patients, to clarify the immune function characteristics of PCOS patients, and to try to establish an evaluation method of the immune function of PCOS patients.

NCT ID: NCT06325956 Recruiting - Clinical trials for Polycystic Ovary Syndrome

PCOS Immune Function Predicts Metformin Efficacy

Start date: March 16, 2024
Phase: N/A
Study type: Interventional

In this study, the investigators will include PCOS patients who meet the trial criteria, introduce participants to the content of this study, and invite participants to participate. The immune function of peripheral blood samples of PCOS patients was detected by flow cytometry. Participants were further treated with metformin for 6 months and followed up after the intervention. The objective of this study was to investigate immune markers related to the efficacy of metformin in PCOS patients and to predict the efficacy of metformin in PCOS patients using immune function.

NCT ID: NCT06325774 Recruiting - Clinical trials for Localized Prostate Cancer

Radical Hypofractionated Radiotherapy for Localized Prostate Cancer

Start date: April 1, 2024
Phase: N/A
Study type: Interventional

The aim of this trial is to study the safety outcomes of hypofractionated radiotherapy in treating patients with localized prostate cancer. Hypofractionated radiotherapy delivers higher doses of radiotherapy in a shorter time period, may enabling the killing of more tumor cells with fewer side effects. Accumulating evidence has proven the safety and feasibility of hypofractionated radiotherapy for localized prostate cancer.But for localized prostate cancer,the optimal dose per fraction of hypofractionated radiotherapy is still on its way.

NCT ID: NCT06325267 Recruiting - Clinical trials for Primary Liver Cancer

Clinical Characteristics of Primary Liver Cancer

Start date: January 1, 2010
Phase:
Study type: Observational

Primary liver cancer (PLC) is the sixth most common malignancy in the world and the third most common cause of malignancy death. In 2020, there were about 905,677 new cases of PLC worldwide, and 830,180 deaths. Despite the availability of a variety of treatments for PLC, the 5-year net survival rate is still only 5% to 30%. How to effectively reduce the disease burden of PLC is a major public health problem that needs to be solved worldwide. The clinical characteristics and prognosis of PLC caused by different pathogenic factors are different. Therefore, it is of great significance to fully identify the risk factors of PLC, be familiar with the clinical characteristics and prognosis of disease development, and understand the relevant monitoring and follow-up strategies for the prevention and treatment of PLC.

NCT ID: NCT06325254 Recruiting - Clinical trials for Metabolic Associated Fatty Liver Disease

Clinical Characteristics of Metabolic Associated Fatty Liver Disease

Start date: January 1, 2010
Phase:
Study type: Observational

Metabolic associated fatty liver disease (MAFLD), which can lead to liver fibrosis, cirrhosis, liver failure and even hepatocellular carcinoma, poses a significant burden on society. With the improvement of living standards and changes in dietary habits, MAFLD patients show a younger and increasing trend, but there is still no specific drug. The clinical features and prognosis of MAFLD may be different with different metabolic disorder phenotypes and treatment measures. Therefore, further systematic study of the clinical characteristics and prognosis of MAFLD patients will be of great significance for the formulation of corresponding clinical prevention and treatment strategies.

NCT ID: NCT06324890 Recruiting - Dry Eye Clinical Trials

PET-CT Imaging Features of Meibomian Glands

Start date: January 31, 2024
Phase:
Study type: Observational

Analysis the results of Dry eye analysis results and PET-CT imaging comprehensively

NCT ID: NCT06324825 Recruiting - Clinical trials for Atrophic Gastritis With Low-grade Intraepithelial Neoplasia

Fuzheng Nizeng Formula for Chronic Atrophic Gastritis With Low-grade Intraepithelial Neoplasia, a Multicenter Randomized Controlled Trial

Start date: October 24, 2022
Phase: N/A
Study type: Interventional

Fuzheng Nizeng Formula (FZNZ) is derived from the classic formula Liujunzi Decoction. Former pilot study found that FZNZ promoted the recovery of gastric atrophy and relieve the relative symptoms. This study is to evaluate its efficacy for chronic atrophic gastritis with low-grade intraepithelial neoplasia, compared with positive control Molduodan granule.